Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Paragon Care: adjusted metrics improve despite statutory loss in fiscal 2026
Paragon Care reports adjusted revenue of 3.7 billion AUD for fiscal 2026, adjusted EBITDA of 97.2 million AUD and an adjusted net profit after tax of 26 million AUD. On a statutory basis there was, however, a net loss of 16 million AUD, mainly due to a 38 million AUD provision for the Infinity Group. Operating cash flow improved strongly to 29.1 million AUD; management plans a share buyback and a review of dividend policy for 2027 but sees uncertainty from fuel costs and net debt of around 2.5 times EBITDA. The stock fell 3.57% after the announcement to $0.135 and is trading near its year low. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 1.08bn | - |
| Gross profit | 45.3m | - |
| Net profit | 3.18m | - |
| EBITDA | 29.14m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €158.53m |
Number of shares | 1.66bn |
52-week high/low | €0.20 - €0.0772 |
| Dividends | No |
Beta | -0.28 |
P/E ratio | -16.15 |
PEG ratio | 0.12 |
P/B ratio | 0.86 |
P/S ratio | 0.07 |
Company profile
Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care blood analyzers, centrifuges, laser technology, IV lines and fluid therapy, and closed system transfer devices for hazardous drugs. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.
| Name | Paragon Care |
| CEO | Carmen Riley |
| Headquarters | Mount Waverley,
vic Australia |
| Website | |
| IPO | 15/10/1999 |
| Employees | 869 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Australian Securities Exchange Ltd | PGC.AX |
Frankfurt | PXS.F |
Düsseldorf | PXS.DU |